Professional Documents
Culture Documents
colon recto
(Tratamiento Adyuvante ECII)
• NO debe ser tratado ningún paciente EC II ?
ASOCIACION DE CIRUJANOS DE
GUATEMALA. SESION JUNIO 2004
CA. DE COLON
(factores pronósticos)
1. Grado penetración tumoral
2. Afección ganglionar. (12)
3. Metástasis
4. Invasión linfo-vascular
5. Grado histológico
6. Obstrucción o perforación
Análisis de Sub grupos B2
intergroup Study
Carcinoma de colon
(factores de mal pronóstico)....
• Inestabilidad microsatelital
• Deleción 18q-
• Niveles de timidilato sintetasa
• Indice de DNA marcado
• Status del inhibidor de ciclo celular
• CEA pre operatorio
FACTORES PRONOSTICOS
Ca. Colon recto EC II
(factores de mal pronóstico)....
• Marcada grado heterogéneo existe entre estadíos
patológicos basados en factores clínicos, patológicos y
moleculares.
MOSAIC
MOSAIC
Oct 98
Enero 01
20 paises
146 centros
23% HR
P= 0.002
Tumour-activated Xeloda
Intestine Liver
5'-DFCR 5'-DFCR
CyD
CyD
5'-DFUR 5'-DFUR
Thymidine
phosphorylase (TP)
5-FU
5'-DFCR = 5'-deoxy-5-fluorocytidine; 5'-DFUR = 5'-deoxy-5-fluorouridine;
CyD = cytidine deaminase; CE = carboxylesterase
TP is significantly more active in
human tumour tissue
No. patients
115
Colorectal
115 *
291
Gastric
351 *
309
Breast
309 *
16 Healthy tissue
Liver (metastasis)
20 * Tumour tissue
0.6
12.8 12.9
0.0
0 5 10 15 20 25 30 35 40 45
Months
0
y U y a y
G d
5G 5-
F 5 l o 5G
+ Xe +
-FU da
5 elo
X
*p<0.05 Sawada N et al. Clin Cancer Res 1999;5:2948–53
Xeloda chemoradiation in rectal
cancer:
German phase II study (n=68)
Day 1 8 15 22 29 35
Radiotherapy
1.8Gy/day plus
presacral boost
(3 x 1.8Gy)
Oral Xeloda
825mg/m twice
2
Continuous (days 1–37)
daily
• Male/female (%) = 63/37; median age = 65 years
ECOG 0/1 54/41
• T3 48%, T4 52%; N0 35%, N1–3 57%
Dunst study 1
Lin study 2
Down-staging 79 73
pRR 80 87
pCR 5 20
2
Lin E et al. Proc Am Soc Clin Oncol 2003;22:287 (Abst 1152)
SOCRATES: Xeloda plus
oxaliplatin and radiotherapy
Dose RT Oxaliplatin Continuous Xeloda
level (Gy)* (mg/m2 every 4 weeks) (mg/m2 twice daily)
1 45 130 500
2 45 130 650
3 45 130 825
• DLTs (2 patients): grade 3 diarrhoea, desquamation/
rectal pain
• Study ongoing in phase II (n=80 total)
*25 fractions Glynne-Jones R et al. Proc Am Soc Clin Oncol 2003;22:292 (Abst 1174)
Early safety results of XELOX-
RT
Duck L et al. ECCO 12 2003 (Abst 260)
*Plus 5.4Gy boost for non-fixed tumours, 10.8Gy for fixed tumours